

10533787

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssspal604dxj

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 NOV 21 CAS patent coverage to include exemplified prophetic
substances identified in English-, French-, German-,
and Japanese-language basic patents from 2004-present
NEWS 3 NOV 26 MARPAT enhanced with FSORT command
NEWS 4 NOV 26 CHEMSAFE now available on STN Easy
NEWS 5 NOV 26 Two new SET commands increase convenience of STN
searching
NEWS 6 DEC 01 ChemPort single article sales feature unavailable
NEWS 7 DEC 12 GBFULL now offers single source for full-text
coverage of complete UK patent families
NEWS 8 DEC 17 Fifty-one pharmaceutical ingredients added to PS
NEWS 9 JAN 06 The retention policy for unread STNmail messages
will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
Classification Data
NEWS 11 FEB 02 Simultaneous left and right truncation (SLART) added
for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13 FEB 06 Patent sequence location (PSL) data added to USGENE
NEWS 14 FEB 10 COMPENDEX reloaded and enhanced
NEWS 15 FEB 11 WTEXTILES reloaded and enhanced
NEWS 16 FEB 19 New patent-examiner citations in 300,000 CA/Cplus
patent records provide insights into related prior
art
NEWS 17 FEB 19 Increase the precision of your patent queries -- use
terms from the IPC Thesaurus, Version 2009.01
NEWS 18 FEB 23 Several formats for image display and print options
discontinued in USPATFULL and USPAT2
NEWS 19 FEB 23 MEDLINE now offers more precise author group fields
and 2009 MeSH terms
NEWS 20 FEB 23 TOXCENTER updates mirror those of MEDLINE - more
precise author group fields and 2009 MeSH terms
NEWS 21 FEB 23 Three million new patent records blast AEROSPACE into
STN patent clusters
NEWS 22 FEB 25 USGENE enhanced with patent family and legal status
display data from INPADOCDB
NEWS 23 MAR 06 INPADOCDB and INPAFAMDB enhanced with new display
formats

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

Jagoe

10533787

NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:01:05 ON 06 MAR 2009

=> FIL REGISTRY	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 16:01:17 ON 06 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 MAR 2009 HIGHEST RN 1116197-74-0
DICTIONARY FILE UPDATES: 5 MAR 2009 HIGHEST RN 1116197-74-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s strontium ranelate/cn
L1 1 STRONTIUM RANELATE/CN


=> d 11

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN 135459-87-9 REGISTRY
ED Entered STN: 09 Aug 1991
CN 3-Thiopheneacetic acid, 5-[bis(carboxymethyl)amino]-2-carboxy-4-cyano-, strontium salt (1:2) (CA INDEX NAME)
OTHER NAMES:
CN Distrontium ranelate
CN Protelos
CN Protos

Jagoe

10533787

CN S 12911
CN S 12911-2
CN Strontium ranelate
MF C12 H10 N2 O8 S . 2 Sr
SR CA
LC STN Files: ADISINSIGHT, AGRICOLA, ANABSTR, BIOSIS, CA, CAPLUS, CASREACT,
CHEMCATS, CIN, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH,
IPA, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, SYNTHLINE, TOXCENTER,
USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO
CRN (135459-90-4)



● 2 Sr

173 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
173 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medline, biosis, adisinsight, agricola, anabstr, ca, caplus, casreact, chemcats,
cin, embase, imsdugnews, imspatents, imspatents, imspatents, imspatents, imspatents, imspatents,
prouddr, synthline, toxcenter, uspat2, uspatful

'PHARM' IS AN AMBIGUOUS FILE OR CLUSTER NAME
PHARMACOLOGY - Pharmaceutical Science Cluster
PHARMAML - Pharma Marketletter 1992 to the present
ENTER FILE OR CLUSTER NAME (IGNORE):phar
COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE	TOTAL
	ENTRY	SESSION
	9.32	9.54

FILE 'MEDLINE' ENTERED AT 16:03:53 ON 06 MAR 2009

FILE 'BIOSIS' ENTERED AT 16:03:53 ON 06 MAR 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'ADISINSIGHT' ENTERED AT 16:03:53 ON 06 MAR 2009
COPYRIGHT (C) 2009 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 16:03:53 ON 06 MAR 2009

FILE 'ANABSTR' ENTERED AT 16:03:53 ON 06 MAR 2009
COPYRIGHT (c) 2009 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'CA' ENTERED AT 16:03:53 ON 06 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 16:03:53 ON 06 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CASREACT' ENTERED AT 16:03:53 ON 06 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CHEMCATS' ENTERED AT 16:03:53 ON 06 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 16:03:53 ON 06 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

FILE 'EMBASE' ENTERED AT 16:03:53 ON 06 MAR 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'IMSDRUGNEWS' ENTERED AT 16:03:53 ON 06 MAR 2009
COPYRIGHT (C) 2009 IMSWORLD Publications Ltd

FILE 'IMSPATENTS' ENTERED AT 16:03:53 ON 06 MAR 2009
COPYRIGHT (C) 2009 IMSWORLD Publications Ltd.

FILE 'IMSPRODUCT' ENTERED AT 16:03:53 ON 06 MAR 2009
COPYRIGHT (C) 2009 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 16:03:53 ON 06 MAR 2009
COPYRIGHT (C) 2009 IMSWORLD Publications Ltd

FILE 'IPA' ENTERED AT 16:03:53 ON 06 MAR 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'MRCK' ENTERED AT 16:03:53 ON 06 MAR 2009
COPYRIGHT (C) 2009 Merck & Co., Inc., Whitehouse Station, New Jersey, USA. All Rights Reserved.

FILE 'PHAR' ENTERED AT 16:03:53 ON 06 MAR 2009
COPYRIGHT (C) 2009 Informa UK Ltd.

FILE 'PROMT' ENTERED AT 16:03:53 ON 06 MAR 2009
COPYRIGHT (C) 2009 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 16:03:53 ON 06 MAR 2009
COPYRIGHT (C) 2009 Prous Science

FILE 'SYNTHLINE' ENTERED AT 16:03:53 ON 06 MAR 2009
COPYRIGHT (C) 2009 Prous Science

FILE 'TOXCENTER' ENTERED AT 16:03:53 ON 06 MAR 2009
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:03:53 ON 06 MAR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:03:53 ON 06 MAR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1
THE ESTIMATED SEARCH COST FOR FILE 'CASREACT' IS 30.70 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
22 FILES SEARCHED...
L2 1371 L1

=> s gastritis or gastroenteritis or duodenal pain or gastric pain or gastroduodenal or
irritable bowel or inflammatory bowel or crohn? or colitis
THE ESTIMATED SEARCH COST FOR FILE 'CA' IS 27.43 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
THE ESTIMATED SEARCH COST FOR FILE 'CAPLUS' IS 29.12 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
THE ESTIMATED SEARCH COST FOR FILE 'CASREACT' IS 27.43 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
8 FILES SEARCHED...
THE ESTIMATED SEARCH COST FOR FILE 'CIN' IS 25.32 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
L3 524457 GASTRITIS OR GASTROENTERITIS OR DUODENAL PAIN OR GASTRIC PAIN
OR GASTRODUODENAL OR IRRITABLE BOWEL OR INFLAMMATORY BOWEL OR
CROHN? OR COLITIS

=> s l2 and l3
L4 35 L2 AND L3

=> dup rem
ENTER L# LIST OR (END):l4
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, CHEMCATS, IMSPATENTS, IMSPRODUCT,
IMRESEARCH, MRCK, PHAR, PROUSDDR, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L4
L5 29 DUP REM L4 (6 DUPLICATES REMOVED)

=> s l5 and pd<2003
1 FILES SEARCHED...
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
7 FILES SEARCHED...
10 FILES SEARCHED...
19 FILES SEARCHED...
L6 0 L5 AND PD<2003

=> s l5 and PD<2004
1 FILES SEARCHED...
'2004' NOT A VALID FIELD CODE
'2004' NOT A VALID FIELD CODE
7 FILES SEARCHED...
10 FILES SEARCHED...
19 FILES SEARCHED...
23 FILES SEARCHED...
L7 2 L5 AND PD<2004

=> d l7 1-2 ibib, kwic, ind

L7 ANSWER 1 OF 2 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
ACCESSION NUMBER: 2003:85442 BIOSIS
DOCUMENT NUMBER: PREV200300085442

TITLE: Osteoporosis in inflammatory bowel disease.
 AUTHOR(S): Compston, J. [Reprint Author]
 CORPORATE SOURCE: Department of Medicine, Addenbrooke's Hospital, Box 157, Cambridge, CB2 2QQ, UK
 jec1001@cam.ac.uk
 SOURCE: Gut, (January 2003) Vol. 52, No. 1, pp. 63-64. print.
 ISSN: 0017-5749 (ISSN print).
 DOCUMENT TYPE: Article
 LANGUAGE: English
 ENTRY DATE: Entered STN: 6 Feb 2003
 Last Updated on STN: 6 Feb 2003
 TI Osteoporosis in inflammatory bowel disease.
 SO Gut, (January 2003) Vol. 52, No. 1, pp. 63-64. print.
 ISSN: 0017-5749 (ISSN print).
 IT . . .
 IT Orthopedics (Human Medicine, Medical Sciences)
 IT Parts, Structures, & Systems of Organisms
 bone: skeletal system; bowel: digestive system
 IT Diseases
Crohn's disease: digestive system disease, immune system disease
Crohn Disease (MeSH)
 IT Diseases
 hypogonadism: endocrine disease/gonads
 Hypogonadism (MeSH)
 IT Diseases
inflammatory bowel disease: digestive system disease, complications, pathology, therapy
Inflammatory Bowel Diseases (MeSH)
 IT Diseases
 osteoporosis: bone disease, complications, pathology, therapy
 Osteoporosis (MeSH)
 IT Chemicals & Biochemicals
 alendronate: metabolic-drug; calcium; cyclic etidronate: . . .
 RN 66376-36-1 (alendronate)
 7440-70-2 (calcium)
 84449-90-1 (raloxifene)
 105462-24-6 (risedronate)
 135459-87-9 (strontium ranelate)
 1406-16-2 (Vitamin D)
 CC Biochemistry studies - General 10060
 Biochemistry studies - Vitamins 10063
 Biochemistry studies - Sterols and steroids 10067
 Biochemistry studies - Minerals 10069
 Pathology - General 12502
 Pathology - Therapy 12512
 Metabolism - General metabolism and metabolic pathways 13002
 Digestive system - Physiology and biochemistry 14004
 Digestive system - Pathology 14006
 Endocrine - Gonads and placenta 17006
 Bones, joints, fasciae, connective and adipose tissue - Physiology and biochemistry 18004
 Bones, joints, fasciae, connective and adipose tissue - Pathology 18006
 Pharmacology - Drug metabolism and metabolic stimulators 22003
 Pharmacology - Clinical pharmacology 22005
 Pharmacology - Endocrine system 22016
 Immunology - Immunopathology, tissue immunology 34508
 IT Major Concepts

Gastroenterology (Human Medicine, Medical Sciences); Metabolism;
Orthopedics (Human Medicine, Medical Sciences)

IT Parts, Structures, & Systems of Organisms
bone: skeletal system; bowel: digestive system

IT Diseases
Crohn's disease: digestive system disease, immune system
disease
Crohn Disease (MeSH)

IT Diseases
hypogonadism: endocrine disease/gonads
Hypogonadism (MeSH)

IT Diseases
inflammatory bowel disease: digestive system
disease, complications, pathology, therapy
Inflammatory Bowel Diseases (MeSH)

IT Diseases
osteoporosis: bone disease, complications, pathology, therapy
Osteoporosis (MeSH)

IT Chemicals & Biochemicals
alendronate: metabolic-drug; calcium; cyclic etidronate:
metabolic-drug; raloxifene: hormone-drug; risedronate: metabolic-drug;
strontium ranelate: metabolic-drug; vitamin D: vitamin-drug

IT Miscellaneous Descriptors
bone mineral density; bone strength; disease comorbidity

ORGN Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human (common): patient, postmenopausal, female
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates

RN 66376-36-1 (alendronate)
7440-70-2 (calcium)
84449-90-1 (raloxifene)
105462-24-6 (risedronate)
135459-87-9 (strontium ranelate)
1406-16-2 (vitamin D)

L7 ANSWER 2 OF 2 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights
reserved on STN

ACCESSION NUMBER: 2004044556 EMBASE

TITLE: [Therapy of osteoporosis: Bisphosphonates, SERM's,
teriparatide and strontium].
Osteoporosebehandlung: Bisphosphonate, SERM's, Teriparatide
und Strontium.

AUTHOR: Uebelhart, D., Dr. (correspondence); Frey, D.;
Frey-Rindova, P.; Michel, B.A.

CORPORATE SOURCE: Rheumaklinik, Inst. für Physikalische Medizin,
Universitätsklinik Zurich, Gloriastrasse 25, 8091 Zurich,
Switzerland. daniel.uebelhart@usz.ch

AUTHOR: Uebelhart, D., Dr. (correspondence)

CORPORATE SOURCE: Department of Biochemistry, Rush Presbyt.-St. Luke's Med.
Center, Chicago, IL, United States. daniel.uebelhart@usz.ch

AUTHOR: Uebelhart, D., Dr. (correspondence); Frey-Rindova, P.;
Goerres, G.

CORPORATE SOURCE: Osteoporose Zentrum U., Zurich CH, Switzerland. daniel.uebe
lhart@usz.ch

AUTHOR: Goerres, G.

CORPORATE SOURCE: Departement Medizinische Radiologie, Klin. und Poliklin.

fur Nuklearmed., Universitatsspital Zurich, Zurich, CH,
Switzerland.

SOURCE: Zeitschrift fur Rheumatologie, (**Dec 2003**) Vol.
62, No. 6, pp. 512-517.
Refs: 34
ISSN: 0340-1855 CODEN: ZRHMBQ

COUNTRY: Germany

DOCUMENT TYPE: Journal; General Review; (Review)

FILE SEGMENT: 030 Clinical and Experimental Pharmacology
033 Orthopedic Surgery
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: German

SUMMARY LANGUAGE: English; German

ENTRY DATE: Entered STN: 12 Feb 2004
Last Updated on STN: 12 Feb 2004

SO Zeitschrift fur Rheumatologie, (**Dec 2003**) Vol. 62, No. 6, pp.
512-517.
Refs: 34
ISSN: 0340-1855 CODEN: ZRHMBQ

CT Medical Descriptors:
bone . . . mineral
breast cancer
cancer incidence
clinical trial
diarrhea: SI, side effect
digestive system perforation: SI, side effect
drug contraindication
drug effect
drug efficacy
drug formulation
drug tolerability
esophagus disease: SI, side effect
fracture
gastroduodenal ulcer: SI, side effect
gastrointestinal hemorrhage: SI, side effect
gastrointestinal symptom: SI, side effect
hormone substitution
human
meta analysis
osteolysis
*osteoporosis: DI, drug therapy
*osteoporosis: PC, prevention
patient compliance
postmenopause. . .

RN. . . 114084-78-5, 138844-81-2, 138926-19-9; (pamidronic acid) 40391-99-9,
57248-88-1; (parathyroid hormone[1-34]) 12583-68-5, 52232-67-4;
(raloxifene) 82640-04-8, 84449-90-1; (risedronic acid) 105462-24-6,
122458-82-6; (strontium ranelate) **135459-87-9**; (strontium)
7440-24-6; (tamoxifen citrate) 54965-24-1; (zoledronic acid) 118072-93-8,
131654-46-1, 165800-06-6, 165800-07-7

CT Medical Descriptors:
bone density
bone metastasis: DI, drug therapy
bone mineral
breast cancer
cancer incidence
clinical trial
diarrhea: SI, side effect
digestive system perforation: SI, side effect

drug contraindication
 drug effect
 drug efficacy
 drug formulation
 drug tolerability
 esophagus disease: SI, side effect
 fracture

gastroduodenal ulcer: SI, side effect

gastrointestinal hemorrhage: SI, side effect
 gastrointestinal symptom: SI, side effect
 hormone substitution
 human
 meta analysis
 osteolysis
 *osteoporosis: DT, drug therapy
 *osteoporosis: PC, prevention
 patient compliance
 postmenopause osteoporosis: DT, drug therapy
 review
 supplementation
 vertebra fracture: DT, drug therapy

CT

Drug Descriptors:
 alendronic acid: AE, adverse drug reaction
 alendronic acid: DT, drug therapy
 alendronic acid: PD, pharmacology
 alfacalcidol: CM, drug comparison
 alfacalcidol: DT, drug therapy
 alfacalcidol: IV, intravenous drug administration
 anabolic agent: DT, drug therapy
 anabolic agent: PO, oral drug administration
 anabolic agent: PD, pharmacology
 *bisphosphonic acid derivative: AE, adverse drug reaction
 *bisphosphonic acid derivative: CT, clinical trial
 *bisphosphonic acid derivative: CM, drug comparison
 *bisphosphonic acid derivative: DT, drug therapy
 *bisphosphonic acid derivative: IV, intravenous drug administration
 *bisphosphonic acid derivative: PD, pharmacology
 calcium: CB, drug combination
 calcium: DT, drug therapy
 estrogen: CB, drug combination
 estrogen: CM, drug comparison
 estrogen: DT, drug therapy
 estrogen: PD, pharmacology
 gestagen: CB, drug combination
 gestagen: CM, drug comparison
 gestagen: DT, drug therapy
 gestagen: PD, pharmacology
 ibandronic acid: AE, adverse drug reaction
 ibandronic acid: DT, drug therapy
 ibandronic acid: IV, intravenous drug administration
 ibandronic acid: PD, pharmacology
 pamidronic acid: AE, adverse drug reaction
 pamidronic acid: DT, drug therapy
 pamidronic acid: IV, intravenous drug administration
 pamidronic acid: PD, pharmacology
 *parathyroid hormone[1-34]: CT, clinical trial
 *parathyroid hormone[1-34]: DT, drug therapy
 *parathyroid hormone[1-34]: PD, pharmacology
 raloxifene: DT, drug therapy
 raloxifene: PD, pharmacology

risedronic acid: AE, adverse drug reaction
 risedronic acid: DT, drug therapy
 risedronic acid: PD, pharmacology
 *selective estrogen receptor modulator: DT, drug therapy
 *selective estrogen receptor modulator: PD, pharmacology
 *strontium: AE, adverse drug reaction
 *strontium: CT, clinical trial
 *strontium: DT, drug therapy
 *strontium: PO, oral drug administration
 *strontium: PD, pharmacology
 *strontium ranelate: AE, adverse drug reaction
 *strontium ranelate: CT, clinical trial
 *strontium ranelate: DT, drug therapy
 *strontium ranelate: PO, oral drug administration
 *strontium ranelate: PD, pharmacology
 tamoxifen citrate: DT, drug therapy
 unclassified drug
 vitamin D: CB, drug combination
 vitamin D: DT, drug therapy
 zoledronic acid: AE, adverse drug reaction
 zoledronic acid: DT, drug therapy
 zoledronic acid: IV, intravenous drug administration
 zoledronic acid: PD, pharmacology
 RN (alendronic acid) 66376-36-1; (alfacalcidol) 41294-56-8; (calcium) 7440-70-2; (ibandronic acid) 114084-78-5, 138844-81-2, 138926-19-9; (pamidronic acid) 40391-99-9, 57248-88-1; (parathyroid hormone[1-34]) 12583-68-5, 52232-67-4; (raloxifene) 82640-04-8, 84449-90-1; (risedronic acid) 105462-24-6, 122458-82-6; (strontium ranelate) 135459-87-9; (strontium) 7440-24-6; (tamoxifen citrate) 54965-24-1; (zoledronic acid) 118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7
 CN actonel; bondronat; evista; fosamax; nolvadex; zometa

=> d his

(FILE 'HOME' ENTERED AT 16:01:05 ON 06 MAR 2009)

FILE 'REGISTRY' ENTERED AT 16:01:17 ON 06 MAR 2009

L1 1 S STRONTIUM RANELATE/CN

FILE 'MEDLINE, BIOSIS, ADISINSIGHT, AGRICOLA, ANABSTR, CA, CAPLUS, CASREACT, CHEMCATS, CIN, EMBASE, IMSDRUGNEWS, IMPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MRCK, PHAR, PROMT, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL' ENTERED AT 16:03:53 ON 06 MAR 2009

L2 1371 S L1
 L3 524457 S GASTRITIS OR GASTROENTERITIS OR DUODENAL PAIN OR GASTRIC PAIN
 L4 35 S L2 AND L3
 L5 29 DUP REM L4 (6 DUPLICATES REMOVED)
 L6 0 S L5 AND PD<2003
 L7 2 S L5 AND PD<2004

=> d 15 1-29 ti

L5 ANSWER 1 OF 29 CA COPYRIGHT 2009 ACS on STN DUPLICATE 1
 TI Modulators of Axl protein activity or Axl gene expression for treating bone disorders and screening drugs

L5 ANSWER 2 OF 29 USPATFULL on STN
 TI Method for Improving the Medical Treatment of Pain

- L5 ANSWER 3 OF 29 USPATFULL on STN
 TI METHODS OF TREATMENT AND PREVENTION OF METABOLIC BONE DISEASES AND DISORDERS
- L5 ANSWER 4 OF 29 USPATFULL on STN
 TI Osteoporosis associated markers and methods of use thereof
- L5 ANSWER 5 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
 TI Ibandronate: A review of its use in the management of postmenopausal osteoporosis.
- L5 ANSWER 6 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
 TI Gut, inflammation and osteoporosis: Basic and clinical concepts.
- L5 ANSWER 7 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
 TI Strontium ranelate for the management of osteoporosis.
- L5 ANSWER 8 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
 TI Mineral and bone disorder after renal transplantation: A review.
- L5 ANSWER 9 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
 TI Ibandronate - A convenient and effective treatment option for the management of post-menopausal osteoporosis.
- L5 ANSWER 10 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
 TI Postmenopausal osteoporosis: Current and future treatment options.
- L5 ANSWER 11 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
 TI The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.
- L5 ANSWER 12 OF 29 USPATFULL on STN
 TI Controlled release composition containing a strontium salt
- L5 ANSWER 13 OF 29 USPATFULL on STN
 TI Use of the distronium salt of the acid
 2-[n,n-di(carboxymethyl)amino]-3-cyano-4-carboxy-
 methyl-thiophene-5-carboxylate for the production of medicaments for the
 treatment of gastro-duodenal pain
- L5 ANSWER 14 OF 29 CA COPYRIGHT 2009 ACS on STN DUPLICATE 2
 TI Preclinical assessment of gastroesophagal tolerance of the new
 antiosteoporotic drug strontium ranelate: an endoscopic study in monkeys
- L5 ANSWER 15 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
 TI Update of current therapeutic options for the treatment of postmenopausal osteoporosis.
- L5 ANSWER 16 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
 TI Strontium ranelate: The first dual action bone agent.

- L5 ANSWER 17 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
- TI The treatment of severe postmenopausal osteoporosis: A review of current and emerging therapeutic options.
- L5 ANSWER 18 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
- TI Addressing and meeting the needs of osteoporotic patients with strontium ranelate: A review.
- L5 ANSWER 19 OF 29 CA COPYRIGHT 2009 ACS on STN DUPLICATE 3
- TI A method of improving the medical treatment of pain
- L5 ANSWER 20 OF 29 CA COPYRIGHT 2009 ACS on STN DUPLICATE 4
- TI A method for preventing gastrointestinal side-effects of a drug or food product
- L5 ANSWER 21 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
- TI Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.
- L5 ANSWER 22 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
- TI Strontium ranelate Fujisawa/Servier.
- L5 ANSWER 23 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
- TI [News in the field of drugs in the year 2004].
Novosti na području lijekova (svijet) u 2004. Godini.
- L5 ANSWER 24 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
- TI [Risk factors, prevention and treatment of osteoporosis: Prevention of fractures].
Risikofaktoren, praevention, therapie: Frakturen moeglichst vorbeugen.
- L5 ANSWER 25 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
- TI Clinical effects of strontium ranelate in women with postmenopausal osteoporosis.
- L5 ANSWER 26 OF 29 CA COPYRIGHT 2009 ACS on STN DUPLICATE 5
- TI Use of the distronium salt of 2-N,N,
di(carboxymethyl)amino-3-cyano-4-carboxymethylthiophene-5-carboxylic acid
(Sr ranelate) for obtaining drugs for the treatment of
gastroduodenal pains
- L5 ANSWER 27 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
- TI The effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis.
- L5 ANSWER 28 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
- TI [Therapy of osteoporosis: Bisphosphonates, SERM's, teriparatide and strontium].
Osteoporosebehandlung: Bisphosphonate, SERM's, Teriparatide und Strontium.

L5 ANSWER 29 OF 29 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on
 STM DUPLICATE 6
 TI Osteoporosis in inflammatory bowel disease.

=> d l29 2-2 ibib, kwic

L29 NOT FOUND

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d his

(FILE 'HOME' ENTERED AT 16:01:05 ON 06 MAR 2009)

FILE 'REGISTRY' ENTERED AT 16:01:17 ON 06 MAR 2009

L1 1 S STRONTIUM RANELATE/CN

FILE 'MEDLINE, BIOSIS, ADISINSIGHT, AGRICOLA, ANABSTR, CA, CAPLUS, CASREACT, CHEMCATS, CIN, EMBASE, IMSDRUGNEWS, IMPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MRCK, PHAR, PROMT, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL' ENTERED AT 16:03:53 ON 06 MAR 2009

L2 1371 S L1

L3 524457 S GASTRITIS OR GASTROENTERITIS OR DUODENAL PAIN OR GASTRIC PAIN

L4 35 S L2 AND L3

L5 29 DUP REM L4 (6 DUPLICATES REMOVED)

L6 0 S L5 AND PD<2003

L7 2 S L5 AND PD<2004

=> d l5 2-2 ibib, kwic

L5 ANSWER 2 OF 29 USPATFULL on STM

ACCESSION NUMBER: 2008:361583 USPATFULL

TITLE: Method for Improving the Medical Treatment of Pain

INVENTOR(S): Christgau, Stephan, Gentofte, DENMARK

Hansen, Christian, Vedbaek, DENMARK

Nilsson, Henrik, Copenhagen K, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080317849	A1	20081225
APPLICATION INFO.:	US 2005-629612	A1	20050617 (11)
	WO 2005-DK401		20050617
			20080304 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2004-947	20040617
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US	
NUMBER OF CLAIMS:	53	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1275	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
SUMM	. . . COX-2 inhibitors is still associated with an increased prevalence of GI side effects compared to placebo treatment. The incidence of <u>gastroduodenal</u> ulcers in COX-2 inhibitor treated patients is generally lower than with nonselective NSAIDs (i.e. NSAIDs	

not specifically developed as selective. . . .

DETD . . . bone cancer pain, neuropathic pain, pain associated with migraine, pain like static allodynia, pain like dynamic allodynia, pain associated with Crohn's disease headache pain and/or pain associated with completion of a large number of patent applications within a limited interval of. . . .

DETD . . . induce gastrointestinal (GI) damage such as epigastric/abdominal pain, nausea, vomiting, diarrhea, dyspepsia, bloating, flatulence, anorexia, mucosal erosions and/or inflammation (esophagitis, gastritis, duodenitis, enteritis), gastrointestinal hemorrhage including hematemesis, melena and hematochezia, (peptic) ulcerations and GI strictures. Increased susceptibility/risk for GI side effects. . . .

CLM What is claimed is:

. . . bone cancer pain, neuropathic pain, pain associated with migraine, pain like static allodynia, pain like dynamic allodynia, pain associated with Crohn's disease and/or headache pain.

IT 50-14-6, Vitamin D2 67-97-0, Vitamin D3 526-26-1, Strontium salicylate 543-94-2, Strontium acetate 592-89-2, Strontium formate 814-95-9, Strontium oxalate 868-19-9, Strontium tartrate 1406-16-2, Vitamin D 1633-05-2, Strontium carbonate 2188-25-2, Strontium benzoate 7440-24-6D, Strontium, salts 7446-28-8, Strontium phosphate 7759-02-6, Strontium sulfate 7783-48-4, Strontium fluoride 10042-76-9, Strontium nitrate 10101-21-0, Strontium gluconate 10476-81-0, Strontium bromide 10476-85-4, Strontium chloride 10476-86-5, Strontium iodide 13451-02-0, Strontium sulfite 13470-06-9, Strontium nitrite 13598-73-7 13703-84-9, Strontium borate 16067-69-9 16088-89-4 18808-42-9 19657-12-6 23287-50-5 29031-19-4D, strontium salts 29870-99-3, Strontium lactate 40182-75-0, Strontium citrate 40302-04-3, Strontium phosphinate 41839-80-9 58429-84-8 59640-09-4, Strontium phthalate 60884-91-5, Strontium trifluoroacetate 135459-87-9 303730-87-2, Strontium L-ascorbate 335059-81-9 796104-84-2 796104-90-0, Strontium mesylate 796104-92-2 796104-97-7 796105-00-5 796105-02-7 796105-04-9 796105-06-1 796105-14-1 796842-36-9 796842-37-0
(controlled-release composition containing strontium salt)

=> d 15 6-6 ibib, kwic

L5 ANSWER 6 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2008198608 EMBASE

TITLE: Gut, inflammation and osteoporosis: Basic and clinical concepts.

AUTHOR: Tilg, Herbert, Dr. (correspondence); Moschen, A.R.; Kaser, A.

CORPORATE SOURCE: Christian Doppler Research Laboratory for Gut Inflammation, Department of Medicine, Medical University Innsbruck, Austria. herbert.tilg@i-med.ac.at

AUTHOR: Pines, A.

CORPORATE SOURCE: Department of Medicine T, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel.

AUTHOR: Dotan, I.

CORPORATE SOURCE: IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

AUTHOR: Tilg, Herbert, Dr. (correspondence)

CORPORATE SOURCE: Christian Doppler Research Laboratory for Gut Inflammation,

Division of Gastroenterology and Hepatology, Medical
University Innsbruck, Anichstrasse 35, 6020 Innsbruck,
Austria. herbert.tilg@med.ac.at
Gut, (May 2008) Vol. 57, No. 5, pp. 684-694.
Refs: 123
ISSN: 0017-5749 CODEN: GUTTAK
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 033 Orthopedic Surgery
037 Drug Literature Index
038 Adverse Reactions Titles
048 Gastroenterology
005 General Pathology and Pathological Anatomy
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 21 May 2008
Last Updated on STN: 21 May 2008
AB Chronic inflammatory disorders such as **inflammatory**
bowel diseases (IBD) affect bone metabolism and are frequently
associated with the presence of osteoporosis. Bone loss is regulated by
various. . .
RN. . . 205944-50-9; (pamidronic acid) 40391-99-9, 57248-88-1; (parathyroid
hormone[1-34]) 12583-68-5, 52232-67-4; (prednisolone) 50-24-8;
(raloxifene) 82640-04-8, 84449-90-1; (risedronic acid) 105462-24-6,
122458-82-6; (strontium ranelate) **135459-87-9**

=> d 15 7-7 ibib, kwic

L5 ANSWER 7 of 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights
reserved on STN
ACCESSION NUMBER: 2008344371 EMBASE
TITLE: Strontium ranelate for the management of osteoporosis.
AUTHOR: Lam, Sum, Prof. (correspondence)
CORPORATE SOURCE: Department of Clinical Pharmacy Practice, College of
Pharmacy and Allied Health Professions, St. John's
University, Queens, NY 11439, United States. Lams1@stjohns.
edu
AUTHOR: Lam, Sum, Prof. (correspondence)
CORPORATE SOURCE: Faculty in Geriatric Pharmacy, Divisions of Geriatric
Medicine and Pharmacy, Winthrop University Hospital,
Mineola, NY, United States. Lams1@stjohns.edu
AUTHOR: Zouzias, Katerina
SOURCE: Consultant Pharmacist, (July 2008) Vol. 23, No. 7, pp.
531-537.
Refs: 27
ISSN: 0888-5109 CODEN: CNPHEB
PUBLISHER: American Society of Consultant Pharmacists, 1321 Duke
Street, Alexandria, VA 22314-3563, United States.
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 006 Internal Medicine
020 Gerontology and Geriatrics
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 21 Aug 2008
Last Updated on STN: 21 Aug 2008
CT Medical Descriptors:

amnesia: . . . side effect
 eczema: SI, side effect
 food and drug administration
 *fragility fracture: CO, complication
 *fragility fracture: DT, drug therapy
 *fragility fracture: ET, etiology
 *fragility fracture: PC, prevention
gastritis: SI, side effect
 gastrointestinal symptom: SI, side effect
 headache: SI, side effect
 hot flush: SI, side effect
 human
 kidney clearance
 kidney failure
 lactation
 leg cramp: SI, side effect
 loose. . .
 RN. . . 138844-81-2, 138926-19-9; (osteocalcin) 136461-80-8; (parathyroid hormone) 12584-96-2, 68893-82-3, 9002-64-6; (phosphorus) 7723-14-0; (raloxifene) 82640-04-8, 84449-90-1; (risedronic acid) 105462-24-6, 122458-82-6; (strontium ranelate) 135459-87-9

=> d 15 11-11 ibib, kwic

L5 ANSWER 11 OF 29 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2007128722 EMBASE
 TITLE: The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.
 AUTHOR: Stevenson, M. (correspondence); Davis, S.; Lloyd-Jones, M.; Beverley, C.
 CORPORATE SOURCE: School of Health and Related Research (SchARR), University of Sheffield, Sheffield, United Kingdom.
 SOURCE: Health Technology Assessment, (Feb 2007) Vol. 11, No. 4, pp. 1-80.
 Refs: 102
 ISSN: 1366-5278 CODEN: HTASFX
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; General Review; (Review)
 FILE SEGMENT: 017 Public Health, Social Medicine and Epidemiology
 030 Clinical and Experimental Pharmacology
 033 Orthopedic Surgery
 036 Health Policy, Economics and Management
 037 Drug Literature Index
 038 Adverse Reactions Titles
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 16 Apr 2007
 Last Updated on STN: 16 Apr 2007

CT Medical Descriptors:
 abdominal . . . interaction
 *fragility fracture: DI, diagnosis
 *fragility fracture: DM, disease management
 *fragility fracture: DT, drug therapy
 *fragility fracture: EP, epidemiology
 *fragility fracture: ET, etiology
 *fragility fracture: PC, prevention
gastritis: SI, side effect

gastrointestinal toxicity: SI, side effect

hip fracture: DI, diagnosis

hip fracture: DM, disease management

hip fracture: DT, drug therapy

hip fracture: EP, . . .

RN (alendronic acid) 66376-36-1; (calcium) 7440-70-2; (fluindostatin)
93957-54-1; (parathyroid hormone[1-34]) 12583-68-5, 52232-67-4;
(raloxifene) 82640-04-8, 84449-90-1; (strontium ranelate)
135459-87-9; (tetracycline) 23843-90-5, 60-54-8, 64-75-5

=> d 15 12-12 ibib, kwic

L5 ANSWER 12 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2006:253908 USPATFULL

TITLE: Controlled release composition containing a strontium salt

INVENTOR(S): Hansen, Christian, Vedbaek, DENMARK
Nilsson, Henrik, Copenhagen, DENMARK
Andersen, Jens E.T., Vedbaek, DENMARK
Christgau, Stephan, Gentofte, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060216358	A1	20060928
APPLICATION INFO.:	US 2004-556150	A1	20040506 (10)
	WO 2004-DK326		20040506
			20060608 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2003-691	20030507
	DK 2003-1043	20030708
	DK 2003-1821	20031219
	US 2003-528409P	20031209 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Jones Day, 222 East 41st Street, New York, NY,
10017-6702, US

NUMBER OF CLAIMS: 61

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 4 Drawing Page(s)

LINE COUNT: 2396

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . pain and isolated hyperphosphatasemia. Other potential causes of secondary osteoporosis in children and adolescents are excessive exercise, amenorrhea, dermatomyositis, asthma, **inflammatory bowel** disease, such as **Crohn's** disease, and muscular dystrophy

IT 50-14-6, Vitamin D2 67-97-0, Vitamin D3 526-26-1, Strontium salicylate 543-94-2, Strontium acetate 814-95-9, Strontium oxalate 868-19-9, Strontium tartrate 1406-16-2, Vitamin D 1633-05-2, Strontium carbonate 2188-25-2, Strontium benzoate 7446-28-8, Strontium phosphate 7759-02-6, Strontium sulfate 7783-48-4, Strontium fluoride 10042-76-9, Strontium nitrate 10101-21-0, Strontium gluconate 10476-81-0, Strontium bromide 10476-85-4, Strontium chloride 10476-86-5, Strontium iodide 13451-02-0, Strontium sulfite 13470-06-9, Strontium nitrite 13598-73-7 13703-84-9, Strontium borate 16067-69-9 16088-89-4 18808-42-9 19657-12-6 23287-50-5 29031-19-4D, strontium salts 29870-99-3, Strontium lactate

10533787

40182-75-0, Strontium citrate 40302-04-3, Strontium phosphinate
41839-80-9 59640-09-4, Strontium phthalate 60884-91-5, Strontium
trifluoroacetate **135459-87-9** 303730-87-2, Strontium
L-ascorbate 335059-81-9 796104-84-2 796104-90-0, Strontium mesylate
796104-92-2 796104-97-7 796105-00-5 796105-02-7 796105-04-9
796105-06-1 796105-14-1 796842-36-9 796842-37-0
(controlled release composition containing strontium salt)